Advertisement

Journal of Natural Medicines

, Volume 73, Issue 1, pp 331–337 | Cite as

Screening for natural medicines effective for the treatment of osteoporosis

  • Ryuichiro SuzukiEmail author
  • Satoshi Fukami
  • Mineko Tomomura
  • Akito Tomomura
  • Yoshiaki Shirataki
Natural Resource Letter
  • 177 Downloads

Abstract

Bone-forming osteoblasts are differentiated from mesenchymal stem cells and dysregulation of this differentiation can lead to osteoporosis. Meanwhile, bone-resorbing osteoclasts are both differentiated and multinucleated from hematopoietic precursor cells of monocyte and/or macrophage lineage. Bone resorption inhibitors such as bisphosphonates and estrogen are used to treat osteoporosis. However, the adverse effects of the long-term use of these medicines are of concern, and so the development of new therapies to ameliorate osteoporosis is desirable. Therefore, in the present study, we screened 22 plant extracts and found that nine methanolic extracts of plants promote the differentiation of MC3T3-E1 cells to osteoblasts. These nine extracts were then evaluated for their inhibitory activity on osteoclast differentiation in RAW264.7 mouse macrophage cells. Of the nine extracts, Daucus carota, Vitis spp., Sasa veitchii, Euptelea polyandra, and Sesamum indicum exhibited pro-osteoblastic and anti-osteoclastic activity with low cytotoxicity, suggesting their potential effectiveness against osteoporosis.

Keywords

Plant extracts Osteoporosis Osteoblast differentiation Osteoclast differentiation MC3T3-E1 cells RAW264.7 mouse macrophage cells 

References

  1. 1.
    Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359(9321):1929–1936CrossRefGoogle Scholar
  2. 2.
    Miyauchi Y, Sato Y, Kobayashi T, Yoshida S, Mori T, Kanagawa H, Katsuyama E, Fujie A, Hao W, Miyamoto K, Tando T, Morioka H, Matsumoto M, Chambon P, Johnson RS, Kato S, Toyama Y, Miyamoto T (2013) HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad USA 110:16568–16573CrossRefGoogle Scholar
  3. 3.
    Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C (1989) The risk of breast cancer after estrogen and estrogen-progestri replacement. N Engl J Med 321:293–297CrossRefGoogle Scholar
  4. 4.
    Horii H, Ueda J, Tamura M, Sakagami H, Tomomura M, Tomomura A, Shirataki Y (2011) Search for new biological activity of Rhinacanthus nasutus extracts. Vivo 25:367–374Google Scholar
  5. 5.
    Hasegawa H, Kido S, Tomomura M, Fujimoto K, Ohi M, Kiyomura M, Kanagae H, Inaba A, Sakagami H, Tomomura A (2010) Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity. J Biol Chem 285:25448–25457CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Pharmacognosy and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical SciencesJosai UniversitySakadoJapan
  2. 2.Integrated Education CenterMeikai UniversityUrayasuJapan
  3. 3.Division of Biochemistry, Department of Oral Biology and EngineeringMeikai University School of DentistrySakadoJapan

Personalised recommendations